

### momentum securities

Small knowledge is small focus...

you miss what you don't look for.

#### Introducing Momentum Securities

02

#### **MOMENTUM SECURITIES**

Momentum Group purchases Imara SP Reid to create Momentum Securities. Focused exclusively on the retail private client market (domestic investments).

2014

04

#### **IFA GROWTH**

**Enhanced distribution focus** to grow **IFA** support and **partnerships.** 

2020



01

#### **IMARA**

Imara SP Reid granted one of South Africa's first full-service stockbroking license by the Johannesburg Stock Exchange.

African market access becomes key competitive advantage.

1938

03

International market access and global product range launched.

2018

#### **WEALTH INTERNATIONAL**

Momentum Securities becomes Momentum Wealth International's preferred international Personal Share Portfolio (iPSP) provider.

2019

Momentum Securities launches market-leading online trading platform, followed by a client mobi app.

2021

05

#### **RESULTS**

Asset base doubles and stockbroker market share increased by over 100% (since 2019).

International new business eclipses that of domestic.

2023


Full **electronic adviser** and **client on-boarding** launched.

2024



# GLOBAL MARKET ACCESS





**R1 685.5 billion** 

assets in custody

R185.3 billion

market capitalisation

650 089

no. of client accounts







#### **Multicurrency Account**

Most currencies



+60

Stock exchanges



#### **Bonds**

Listed and OTC



#### Card

Multi-currency



- Discretionary
- Advisory
- Stockbroking
- Individual accounts
- Asset Swaps
- MWI endowment



#### **ETF**

Exchange Traded Funds



30'000

Investment funds



#### **Fiduciary**

Deposits



#### Loans

Gearing



#### **Online channels**

Desktop and App



#### **Structured Products**

Booking of most issuers





# TWELVE CURRENCIES. ZERO FEES.




ONE CARD.

Travel, shop and trade the world

No minimum

REAL TIME **ACCESS** 24/7
















Today \_\_\_\_ 10 000 BC








DNA RETRIEVAL FROM FOSSILS


This is DNA decoding and the **new dawn** of genetics.



RE-CODE AND FILL GENETIC CODE WITH CORE CHARACTERISTICS



ARTIFICIAL INSEMINATION TO DENUCLEATED EMBRYO CELLS






### HUNTED TO ZERO


1 THYLACINE EXTINCT SINCE 1936 1

Giant Moa
New Zealand
Extinct for 600 years

Tasmanian Tiger
New Guinea
Extinct for 2000 years











PROJECT MAMMOT



ELIMINATE EEHU AND OTHER DISEASE














874487488444

# 1,000,000

ANIMAL AND PLANT SPECIES ARE THREATENED WITH EXTINCTION.

SINCE 1990, NATIVE SPECIES OF MOST LAND HABITATS HAVE FALLEN 20%.

MORE THAN

40%

1

33%



AT LEAST

680 VERTEBRATE SPECIES

HAVE BEEN DRIVEN TO EXTING ON SINCE THE 16TH CENTURY.


AND MORE THAN 1/3
OF ALL MARINE
MAMMALS
ARE THREATENED.

BRINGI BACK MAMMOT For the PLANET.


For the ANIMALS.

For the FUTURE.

We are evolving for the sake of tomorrow.



South China Tiger China (obviously) Fewer than 100





#### Genome modification business positioning

Company	Exposure* Impact (implication)	Rating (Equity)
Gene modification		
Alnylam Pharmaceuticals	•••	****
Amgen	•••	Hold
AstraZeneca	••• AstraZeneca	Buy
BB Biotech	•••	Buy
Beigene	•••	n.c.
Biomarin Pharmaceutical	•••	Hold
Biontech <sup>1</sup>	•••	*
Bristol Myers	•••	Buy
Crispr <sup>1</sup>	•••	***
Curevac¹	•••	**
Gilead	•••	Hold
GlaxoSmithKlien	•••	Hold
Hutchison China MediTech	•••	n.c.
Illumina	•••	Hold
Innovent Biologics <sup>1</sup>	•••	**
Inovio <sup>1</sup>	••	***
Merck KGAA	•••	Buy
Moderna	•••	Hold
Morphosys	•••	Buy
Novartis	•••	Hold
Pfizer	•••	Hold
Qiagen <sup>1</sup>	•••	*
Quantum Genomics	••	n.c.
Regeneron <sup>1</sup>	•••	***
Sanofi	•••	Buy
Sarepta Therapeutics	•••	***
Takeda Pharma¹	•••	****
Tecan	•••	Hold
Wuxi Biologics	•••	n.c.


#### Gene testing business positioning

Company	Exposure* Impact (implication)	Rating (Equity)
Gene testing		
Abbott Laboratories	··· Abbott	Buy
Agilent Technologies <sup>1</sup>	••	**
BGI Genomics	•••	n.c.
Danaher	••	Hold
Genmark Diagnostics	•••	n.c.
Illumina	•••	Hold
Myriad Genetics <sup>1</sup>	•••	***
Natera	•••	n.c.
Pacific Biosciences of California	•••	n.c.
Perkinelmer	••	n.c.
Quest Diagnostics <sup>1</sup>	•••	***
Roche	•••	Buy
Seegene	••	n.c.
Sysmex	•••	n.c.
Thermo Fisher Scientific	ThermoFisher	Buy
	SCIENTIFIC	
•••••	•••••	
	•••••	
••••••	••••••	• • •



#### Contract research organization: Business positioning

Company	Exposure* Impact (implication)	Rating (Equity)
Contract research organisations		
Bachem¹	•••	*
Catalent	•••	n.c.
Charles River Laboratories	•••	*
Eurofins Sccientificc	•••	n.c.
ICON¹	•••	**
IQVIA <sup>1</sup>	•••	***
Lonza	•••	***
Medpace	•••	n.c.
PPD	•••	n.c.
Pra Health Sciences	•••	n.c.






R15 390.5 billion

## Momentum Wealth International

Welcome to our offshore investment platform, where investing in various options in 1 place has never been easier. Investing offshore can seem tricky, but with more than 20 years of delivering excellence and the latest technology at your fingertips, we make it a personalised and exciting journey for you.






#### More information on Momentum Securities







#### momentum securities

Disclaimer: This should not be construed as advice. Please note: if you have a discretionary or advisory portfolio, your needs analysis and proposal may not be in line with this content as the investment timelines may differ. The content hereof is not aimed at long-term investment. Clients are encouraged to consult their Portfolio Manager or Stockbroker before making investment decisions. Shares are generally medium-to long-term investments. The value of shares may go down as well as up and past performance is not necessarily a guide to the future. Opinions expressed in this document are those held as at the date appearing in this material only. Momentum Securities shall not be liable or responsible for any use of this document or to any other person or entity for any inaccuracy of information contained in this document or any errors or omissions in its content, regardless of the cause of such inaccuracy, error or omission. This document should not be seen as an offer to purchase any specific product and should not be construed as advice or guidance in any form whatsoever.

